Durham, NC (Vocus/PRWEB) April 07, 2011
AlphaMed Press announces the launch of a major peer-reviewed journal, STEM CELLS Translational Medicine (SCTM), answering an acknowledged need within the research and clinical communities for comprehensive coverage of stem cell science, stem cell-based regenerative medicine and tissue engineering, stem cell-based predictive toxicology, and cancer stem cell investigation.
STEM CELLS Translational Medicine will publish high-impact, peer-reviewed articles that will significantly advance the clinical utilization of stem cell molecular and cellular biology by bridging stem cell research and clinical trials. In addition to original manuscripts, case studies, and commentaries this unique journal will encourage researchers to submit data from their negative clinical trials for publication to rapidly share results that other researchers may find valuable.
The potential of stem cells therapies and regenerative medicine is both provocative and unique, offering the distinct possibility of eventually repairing or replacing tissues damaged from disease, including certain cancers. Under the leadership of the esteemed scientist-clinician Anthony Atala, MD as Editor, STEM CELLS Translational Medicine will speed expertly executed translations of emerging lab discoveries into noteworthy clinical trials.
“This exciting new journal will foster the proper growth and ethical development in this fast-moving field. There is a gap in the existing stem cells journal spectrum that STEM CELLS Translational Medicine will fill,” said Dr. Atala. “SCTM is the sister journal to STEM CELLS, the thirty-year-old premier journal in the field, and together they will elevate our science to applications that will impact the lives of many patients.”
The California Institute for Regenerative Medicine (CIRM) has provided a 3-year seed grant in support of the publication of SCTM.
“Science moves forward through publications in outstanding, peer-reviewed journals,” said Dr. Alan Trounson, CIRM President. “This new journal will provide a venue for studies that move stem cell research closer toward clinical trials. In addition to publishing new discoveries that help all scientists in their goals the journal will also take the unusual step of publishing studies considered “negative,” with results that did not back up the original hypothesis or that did not show a new path to therapies, which will save other scientists the time of carrying out those experiments.”
In addition, the journal will launch a multi-media platform, allowing for the production of series of online podcasts that focus on methods or clinical processes and feature key opinion leaders and thought-provoking roundtables to highlight important issues or feature premier stem cells institutes and laboratories.
SCTM will be available in December 2011.
- Combined Gene Therapy and Stem Cell Transplantation for SCI
- Spinal cord epidural stimulation effects on urogenital and bowel outcomes
- Rapid and robust recovery of breathing 1.5 years after cervical spinal cord injury
- Dimensions matter: Why do the spinal cords of humans and rodents respond differently to epidural electrical stimulation
- Hybrid peripheral-spinal neuromodulation therapies enable refined locomotion after paralysis by combining global and local control of leg movements
- Spatiotemporal neuromodulation of the spinal cord combined with robot-assisted training in humans with spinal cord injury (STIMO): Technological and conceptual framework
- Repairing the Neural Highway by David Holmes in Nature Outline
- Therapeutic impact of grafted oligogenic-directly reprogrammed neural precursor cells and chondroitinase ABC for chronic spinal cord injury
- Long Term Neural Stem Cell Transplant to repair Spinal Cord Injury: neurogenesis, gliogenesis and axon persistence
- Molecular controls over corticospinal motor neuron segmental targeting
- Novel induction of neural-ectoderm and differentiation of neural progenitors from human iPSCs using pressure
- Differentiation and single cell RNA sequencing of V2a interneurons from human pluripotent stem cells
- Dr. Paul J. Reier presents at Working 2 Walk 2017
- Partnership Hopes to Bring Breakthrough Epidural Stimulator Technologies to Millions
- Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders
Follow on TwitterMy Tweets